Laguna Coalesces Around Effort To Treat A-Fib With A Pill Rather Than Electric Shock
This article was originally published in The Pink Sheet Daily
Executive Summary
An oral drug that could replace direct current cardioversion as the standard for restoring normal sinus rhythm in atrial fibrillation patients could be both more patient-friendly and a cost-saver for the health care system.
You may also be interested in...
ChanRx Corp.
Like many a start-up before it, ChanRx Corp. aims to repurpose a compound discovered by others for a new use. Unlike most repurposing efforts, however, this compound, called vanoxerine, has never actually been approved as a drug. Although it has thrice been taken into Phase I trials that yielded acceptable safety data, the compound showed no efficacy for treatment of Parkinson’s disease, depression or cocaine addiction. Noting that vanoxerine could influence muscle that beats rapidly, the start-up is developing it as an oral treatment for atrial fibrillation.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.